Study to evaluate the safety of MAQ-001 as monotherapy and combination therapy in patients with advanced cancers

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-507774-41-00

Acronym

MQ01

Enrollment

Registered

2024-02-19

Start date

2024-05-29

Completion date

Unknown

Last updated

2025-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced cancer histologies for which immune checkpoint blockade is an approved treatment option, and Gastric cancer., Hepatocellular Carcinoma (HCC), Hodgkin’s lymphoma, Lung cancer, Microsatellite Instability (MSI)-high colon cancer, Renal Cell Carcinoma (RCC), such as: Metastatic melanoma

Interventions

None listed

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Countries

France

Outcome results